Towards intelligent anticancer drug screening in the post-genome era?
Workman, P.
Anti-Cancer Drug Design 12(7): 525-531
1997
ISSN/ISBN: 0266-9536 PMID: 9365499 Document Number: 476079
Document emailed within 1 workday
Related Documents
Hagiwara, A.; Takahashi, T. 1987: A new drug-delivery-system of anticancer agents: activated carbon particles adsorbing anticancer agents In Vivo 1(4): 241-252Bolander, F.F. 2010: Intelligent design: drug targets for the prevention of osteoporosis Current Opinion in Investigational Drugs 11(4): 382-384
Zhou, X.-w. 2002: Proteomics in post-genome era and its application in pharmacy Yao Xue Xue Bao 37(10): 828-832
Chimchang, J.; Theparee, T.; Wongein, S.; Trivirot, T.; Tanasupawa, S.; Taweechotipatr, M.; Wongsatayanon, B. 2016: Screening of Potential Probiotic Lactic Acid Bacteria with Anticancer Properties Journal of the Medical Association of Thailand 99(Suppl 8): S70-S78
Jekunen, A.; Lehtovirta, P.; Pyrhönen, S. 1994: Paclitaxel, a new anticancer drug Duodecim; Laaketieteellinen Aikakauskirja 110(13): 1235-1240
Saito, T. 1988: An anticancer drug--carboquone Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 549-554
Williams, M. 2003: Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia Current Opinion in Investigational Drugs 4(1): 31-36
Thanki, K.H.; Bapat, C.V. 1971: Rapid screening of anticancer compounds: an adaptation of agarplate method in tissue culture Indian Journal of Medical Research 59(1): 35-44
1975: Doxorubicin (Adriamycin)--a new anticancer drug Medical Letter on Drugs and Therapeutics 17(10): 42-43
Akazawa, S.; Yamashina, T.; Konuma, Y.; Takahashi, M.; Ueno, A. 2001: Management of anticancer drug adverse reactions Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 4): 409-414
Yamada, T.; Tanaka, N.; Yokoi, K.; Ishikawa, N.; Seya, T.; Horiba, K.; Kanazawa, Y.; Shirakawa, T.; Ohkawa, K.; Kudoh, H.; Koizumi, M.; Yoshioka, M.; Tajiri, T. 2007: Substance P and anticancer drug-induced emesis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(6): 903-906
Li Dapeng 2005: The anticancer drug Kang-Lai-Te emulsion for infusion Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 2005(9): 32-37
Jin, G.; Shen, H. 2015: Cancer risk prediction in post-genome-wide association study era Zhonghua Liu Xing Bing Xue Za Zhi 36(10): 1045-1046
Mauri, D.; Kamposioras, K.; Polyzos, N.P.; Rivas Flores, F.J.; Altinoz, H.; Chojnacka, M.; Karentzou, I.; Dambrosio, M.; Colichi, C.; Oxiuzova, T.; Kanavoura, E.; da Silva Alves de Sousa, B.A.M.; Ivanova, D.; Mauri, J.; Karampoiki, V.; Maragkaki, A.; Xilomenos, A. 2006: Rethinking anticancer screening strategies saving lives at front line. Results from SESy_Europe task force Experimental Oncology 28(3): 252-253
Capel, I.D.; Leach, D.; Dorrell, H.M. 1983: Vitamin e retards the lipoperoxidation resulting from anticancer drug administration Anticancer Research 3(1): 59-62
Bins, S.; Schellens, J.H.M.; Voest, E.E.; Sleijfer, S. 2014: Drug research in oncology; advances in the genome era Nederlands Tijdschrift Voor Geneeskunde 158: A6801
Hsiang, Y.H.; Liu, L.F. 1988: Identification of mammalian DNA topoisomerase i as an intracellular target of the anticancer drug camptothecin Cancer Research 48(7): 1722-1726
Abe, T.; Sasaki, M.; Nakajima, H.; Ogita, M.; Naitou, H.; Nagase, A.; Taguchi, K.; Miyazaki, S. 1990: Evaluation of pluronic F127 as a base for gradual release of anticancer drug Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(8 Part 2): 1546-1550
Ju, X.; Chu, L.; Li, Y. 2004: Study on thermo-sensitive intelligent targeting type drug carriers (I) porous membranes with grafted thermo-sensitive gates Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 21(5): 791-794
Ando, B.; Inoue, K.; Koga, S.; Ibayashi, H.; Ando, S. 1986: An unresectable case of hepatoma completely disappearing after oral administration of an anticancer drug (UFT) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(11): 3261-3265